Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMPH Amphastar Pharmaceuticals	$30.21 -0.9%	$23.67	$20.39 ▼ $53.96	$1.42B	0.76	626,533 shs	464,374 shs
COLL Collegium Pharmaceutical	$37.16 -1.8%	$31.39	$23.23 ▼ $42.29	$1.19B	0.68	375,312 shs	403,902 shs
IMAB I-Mab	$5.16 +21.7%	$2.55	$0.60 ▼ $5.35	$345.57M	1.38	3.67 million shs	5.57 million shs
XERS Xeris Biopharma	$7.30 +0.3%	$5.16	$2.48 ▼ $7.61	$1.18B	0.65	3.04 million shs	2.19 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMPH Amphastar Pharmaceuticals	+0.43%	+46.40%	+38.86%	+25.33%	-30.03%
COLL Collegium Pharmaceutical	-0.03%	+27.26%	+15.32%	+29.04%	+3.13%
IMAB I-Mab	+10.13%	+13.37%	+98.13%	+379.10%	+300.00%
XERS Xeris Biopharma	-0.34%	+32.51%	+33.73%	+51.88%	+186.42%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMPH Amphastar Pharmaceuticals	3.4429 of 5 stars	1.3	2.0	3.7	2.5	4.2	1.3
COLL Collegium Pharmaceutical	3.0035 of 5 stars	2.5	1.0	3.0	2.0	0.8	1.3
IMAB I-Mab	2.9447 of 5 stars	3.7	5.0	0.0	1.9	1.7	0.0
XERS Xeris Biopharma	2.7688 of 5 stars	1.4	1.0	4.2	2.6	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMPH Amphastar Pharmaceuticals	2.50	Moderate Buy	$31.50	4.27% Upside
COLL Collegium Pharmaceutical	3.00	Buy	$42.33	13.92% Upside
IMAB I-Mab	3.33	Buy	$6.00	16.28% Upside
XERS Xeris Biopharma	2.83	Moderate Buy	$6.58	-9.82% Downside

Current Analyst Ratings Breakdown

Latest IMAB, AMPH, XERS, and COLL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	AMPH Amphastar Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$36.00
8/12/2025	XERS Xeris Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$10.00
8/11/2025	COLL Collegium Pharmaceutical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$44.00
8/8/2025	AMPH Amphastar Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$30.00 ➝ $25.00
7/9/2025	IMAB I-Mab	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
7/9/2025	IMAB I-Mab	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
6/27/2025	IMAB I-Mab	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.00 ➝ $5.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMPH Amphastar Pharmaceuticals	$731.97M	1.92	$4.96 per share	6.09	$16.29 per share	1.85
COLL Collegium Pharmaceutical	$631.45M	1.85	$12.10 per share	3.07	$7.37 per share	5.04
IMAB I-Mab	$3.89M	108.11	N/A	N/A	$2.47 per share	2.09
XERS Xeris Biopharma	$203.07M	5.80	N/A	N/A	($0.12) per share	-60.83

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMPH Amphastar Pharmaceuticals	$159.52M	$2.67	11.31	9.18	N/A	18.64%	20.76%	9.68%	N/A
COLL Collegium Pharmaceutical	$69.19M	$1.04	35.73	6.17	N/A	5.13%	97.28%	13.87%	N/A
IMAB I-Mab	-$22.23M	N/A	0.00	N/A	N/A	N/A	-19.81%	-18.63%	8/27/2025 (Estimated)
XERS Xeris Biopharma	-$54.84M	-$0.21	N/A	N/A	N/A	-13.01%	N/A	-8.00%	N/A

Latest IMAB, AMPH, XERS, and COLL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/27/2025	Q2 2025	IMAB I-Mab	-$0.10	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	XERS Xeris Biopharma	-$0.03	-$0.01	+$0.02	-$0.01	$64.58 million	$67.71 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMPH Amphastar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
COLL Collegium Pharmaceutical	N/A	N/A	N/A	N/A	N/A
IMAB I-Mab	N/A	N/A	N/A	N/A	N/A
XERS Xeris Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMPH Amphastar Pharmaceuticals	0.80	3.29	2.21
COLL Collegium Pharmaceutical	3.27	1.18	1.10
IMAB I-Mab	N/A	22.35	22.35
XERS Xeris Biopharma	N/A	1.95	1.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMPH Amphastar Pharmaceuticals	65.09%
COLL Collegium Pharmaceutical	N/A
IMAB I-Mab	38.38%
XERS Xeris Biopharma	42.75%

Insider Ownership

Company	Insider Ownership
AMPH Amphastar Pharmaceuticals	27.50%
COLL Collegium Pharmaceutical	2.51%
IMAB I-Mab	22.10%
XERS Xeris Biopharma	6.47%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMPH Amphastar Pharmaceuticals	2,028	46.49 million	33.71 million	Optionable
COLL Collegium Pharmaceutical	210	31.50 million	30.71 million	Optionable
IMAB I-Mab	380	81.50 million	63.49 million	Optionable
XERS Xeris Biopharma	290	161.48 million	151.03 million	Optionable

IMAB, AMPH, XERS, and COLL Headlines

Recent News About These Companies

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Director Sells $309,400.00 in Stock

August 14 at 7:54 AM | insidertrades.com

Xeris Biopharma (NASDAQ:XERS) Rating Increased to Buy at HC Wainwright

August 14 at 2:13 AM | americanbankingnews.com

Xeris Biopharma's (XERS) "Buy" Rating Reaffirmed at HC Wainwright

August 13 at 8:35 AM | marketbeat.com

Informed Momentum Co LLC Grows Stock Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

August 13 at 6:27 AM | marketbeat.com

Xeris Biopharma assumed with a Buy at H.C. Wainwright

August 12 at 5:49 PM | msn.com

Xeris Biopharma (XERS) Upgraded to Buy: Here's Why

August 12 at 1:01 PM | zacks.com

Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run?

August 12 at 10:16 AM | zacks.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) is Knott David M Jr's 7th Largest Position

August 12 at 8:17 AM | marketbeat.com

Xeris Biopharma (NASDAQ:XERS) Raised to Strong-Buy at Wall Street Zen

August 11 at 2:59 AM | americanbankingnews.com

Xeris Biopharma (NASDAQ:XERS) Releases Earnings Results, Beats Expectations By $0.02 EPS

August 10, 2025 | marketbeat.com

Critical Survey: Xeris Biopharma (NASDAQ:XERS) versus CASI Pharmaceuticals (NASDAQ:CASI)

August 10, 2025 | americanbankingnews.com

Xeris Biopharma (NASDAQ:XERS) Upgraded to "Strong-Buy" at Wall Street Zen

August 10, 2025 | marketbeat.com

Xeris Biopharma (NASDAQ:XERS) Sees Strong Trading Volume After Better-Than-Expected Earnings

August 10, 2025 | americanbankingnews.com

Xeris Biopharma (NASDAQ:XERS) Sees Strong Trading Volume Following Better-Than-Expected Earnings

August 9, 2025 | marketbeat.com

Xeris Biopharma Holdings Second Quarter 2025 Earnings: Beats Expectations

August 9, 2025 | finance.yahoo.com

Xeris Biopharma (NASDAQ:XERS) Hits New 12-Month High After Earnings Beat

August 9, 2025 | americanbankingnews.com

Xeris Biopharma (NASDAQ:XERS) Hits New 12-Month High After Strong Earnings

August 8, 2025 | marketbeat.com

Xeris Biopharma Holdings, Inc. (XERS) Q2 2025 Earnings Call Transcript

August 7, 2025 | seekingalpha.com

Xeris Biopharma (XERS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

August 7, 2025 | zacks.com

Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates

August 7, 2025 | zacks.com

Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance

August 7, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMAB, AMPH, XERS, and COLL Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

$30.21 -0.27 (-0.89%)

Closing price 04:00 PM Eastern

Extended Trading

$30.28 +0.06 (+0.22%)

As of 07:11 PM Eastern

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Collegium Pharmaceutical NASDAQ:COLL

$37.16 -0.70 (-1.85%)

Closing price 04:00 PM Eastern

Extended Trading

$37.26 +0.11 (+0.28%)

As of 06:12 PM Eastern

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

I-Mab NASDAQ:IMAB

$5.16 +0.92 (+21.70%)

Closing price 04:00 PM Eastern

Extended Trading

$5.18 +0.02 (+0.39%)

As of 07:57 PM Eastern

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

Xeris Biopharma NASDAQ:XERS

$7.30 +0.02 (+0.27%)

Closing price 04:00 PM Eastern

Extended Trading

$7.31 +0.01 (+0.14%)

As of 07:40 PM Eastern

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time